Profiel
Edward D.
Wirth worked as the Chief Medical Officer at Asterias Biotherapeutics, Inc. from 2013 to 2019.
Prior to that, he was the Chief Science Officer at InVivo Therapeutics Corp.
in 2012, the Chief Medical Officer at Lineage Cell Therapeutics, Inc., and the Medical Director-Regenerative Medicine Division at Geron Corp.
from 2004 to 2011.
Wirth earned two doctorate degrees from the University of Florida in 1992 and 1994.
Eerdere bekende functies van Edward D. Wirth
| Bedrijven | Functie | Einde |
|---|---|---|
| ASTERIAS BIOTHERAPEUTICS INC | Hoofd Techniek/Wetenschap/O&O | 01-03-2019 |
InVivo Therapeutics Corp.
 InVivo Therapeutics Corp. BiotechnologyHealth Technology InVivo Therapeutics Corp. operates as a medical device company that develops groundbreaking technologies for the treatment of spinal cord injuries. The company was founded by Joseph P. Vacanti and Robert S. Langer, Jr. in 2005 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | 01-09-2012 |
| GERON CORPORATION | Corporate Officer/Principal | 01-10-2011 |
| LINEAGE CELL THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Edward D. Wirth
| University of Florida | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
InVivo Therapeutics Corp.
InVivo Therapeutics Corp. BiotechnologyHealth Technology InVivo Therapeutics Corp. operates as a medical device company that develops groundbreaking technologies for the treatment of spinal cord injuries. The company was founded by Joseph P. Vacanti and Robert S. Langer, Jr. in 2005 and is headquartered in Cambridge, MA. | Health Technology |
